Vilazodone Treatment for Marijuana Dependence

Status Active, not recruiting

Clinical Trial Summary

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.

Clinical Trial Description

The purpose of this study is to determine if the medication vilazodone is effective in helping frequent marijuana smokers cut down or stop using marijuana. Vilazodone is FDA approved for the treatment of depression- in this study, vilazodone's effect on marijuana dependence is being investigated.

Participation in the study takes 10 visits over a period of approximately two to three months. The first visit is a screening visit to determine if participants are eligible to participate. After the initial assessment visit, the weekly visits take about 30 minutes, with the exception of three therapy sessions which take approximately 60-90 minutes. The three therapy sessions will focus on participant's marijuana use and reasons they may have for stopping or cutting down on use. After completing an initial therapy session, participants will be randomly selected to receive the study medication, either vilazodone or placebo (a capsule that does not contain any active medication). Participants will have weekly study visits with a clinician. At each study visit, they will be asked to fill out forms and answer specific questions concerning their substance use, anxiety symptoms, and feelings in general. They will be providing urine samples to check for illegal drugs of abuse including marijuana and other drugs. They will also have blood samples drawn during to determine if you are taking the medication as directed. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01574183
Study type	Interventional
Source	Medical University of South Carolina
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 2012
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00875836` - Buspirone Treatment for Marijuana Dependence	Phase 4
Completed	`NCT00893269` - The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep	Phase 1
Completed	`NCT00490269` - Ph1 Marinol Interaction Study - Part 2 - 1	Phase 1
Completed	`NCT02579421` - Hormones and Reduction in Co-users of Marijuana and Nicotine	N/A
Terminated	`NCT01598896` - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia	Phase 2/Phase 3
Completed	`NCT00373295` - Effect of Baclofen on Marijuana Withdrawal and Relapse	Phase 2
Active, not recruiting	`NCT01827332` - Effect of Oxytocin on Craving and Therapy Response	N/A
Completed	`NCT01335789` - Effect of Oxytocin on Stress in Marijuana Users	N/A
Terminated	`NCT00438139` - Ph1 Marinol Interaction Study - Part 1 - 1	Phase 1
Completed	`NCT02955329` - Vaping THC From Electronic Cigarettes	Phase 3
Completed	`NCT02439814` - Pregnenolone and Marijuana Dependence	Phase 2
Completed	`NCT01347762` - Nabilone for Cannabis Dependence: A Pilot Study	Phase 2/Phase 3
Completed	`NCT01039415` - Attempts to Stop/Reduce Marijuana Among Dependent Users	N/A
Completed	`NCT00270803` - The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana	N/A
Completed	`NCT01020019` - Combined Pharmacotherapy for Cannabis Dependency	Phase 2/Phase 3
Completed	`NCT02030665` - Marijuana Treatment Project 4	N/A
Completed	`NCT00107588` - Marijuana Treatment Project - 3	N/A
Completed	`NCT02011516` - Baclofen Effects on Marijuana Dependence	Phase 2
Recruiting	`NCT00598052` - Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy	N/A
Completed	`NCT00350649` - Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.